Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University Hospital Inselspital, Berne Swiss National Science Foundation |
---|---|
Information provided by: | University Hospital Inselspital, Berne |
ClinicalTrials.gov Identifier: | NCT00622973 |
Preoperative detection of lymph node metastases in patients with prostate or bladder cancer is crucial for selection of the appropriate treatment strategy (surgery, androgen deprivation with/or without radiation therapy or chemotherapy) and thus for patient prognosis. Until now CT or MRI have been the modalities of choice for preoperative staging procedures. However, current morphological assessment of lymph nodes based on size and shape is unable to detect smaller metastases or liable to give false positive results on lymph nodes with reactive hyperplasia. We hypothesize that USPIO-enhanced MRI combined with DW-MRI will be able to detect pelvic lymph node metastases preoperatively with high sensitivity and specificity.
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer Bladder Cancer |
Other: Imaging: diffusion-weighted MRI Other: Sinerem (USPIO) enhanced MRI |
Phase III |
Study Type: | Interventional |
Study Design: | Diagnostic, Non-Randomized, Open Label, Factorial Assignment, Efficacy Study |
Official Title: | Noninvasive Detection of Clinically Occult Lymph Node Metastases in Prostate and Bladder Cancer Evaluated by USPIO-Enhanced MRI and Diffusion-Weighted MRI: A Histopathological Correlation |
Estimated Enrollment: | 90 |
Study Start Date: | September 2007 |
Estimated Study Completion Date: | January 2011 |
Estimated Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A
Diffusion-weighted MRI
|
Other: Imaging: diffusion-weighted MRI
Diffusion-weighted MRI of the entire pelvis to detect lymph node metastases
|
B
Sinerem (USPIO)- enhanced MRI
|
Other: Sinerem (USPIO) enhanced MRI
USPIO (Sinerem) will be administered intravenously immediately after the first MR examination at a dose of 2.6 mg Fe/kg body weight diluted in 100 ml of saline (optimal dose according to: (9, 10)) during a period of about 30 minutes under medical supervision. Postcontrast MR imaging will be performed 24-36 hours after contrast medium injection.
|
Ages Eligible for Study: | 18 Years to 90 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Harriet C Thoeny, MD | +41316322111 ext 6199 | harriet.Thoeny@insel.ch |
Contact: Frederic Birkhaeuser, MD | +41316322111 ext 8801 | frederic.birkhaeuser@insel.ch |
Switzerland | |
Inselspital | Recruiting |
Bern, Switzerland, 3010 | |
Contact: Harriet C Thoeny, MD +41316322111 ext 6199 harriet.thoeny@insel.ch | |
Contact: Frederic Birkhaeuser, MD +41316322111 ext 8801 frederic.birkhaeuser@insel.ch | |
Principal Investigator: Harriet C Thoeny, MD |
Principal Investigator: | Harriet C Thoeny, MD | University Hospital Inselspital, Bern, Switzerland |
Responsible Party: | University Hospital Inselspital, Berne ( Harriet C. Thoeny, MD ) |
Study ID Numbers: | SNF320000-113512/1, KEK101_06, SNF320000-113512/1, SWISSMEDIC2007DR3215 |
Study First Received: | February 13, 2008 |
Last Updated: | January 19, 2009 |
ClinicalTrials.gov Identifier: | NCT00622973 History of Changes |
Health Authority: | Switzerland: Swissmedic |
Prostate cancer Bladder cancer Pelvic lymph node metastases Diffusion-weighted MRI |
Sinerem (USPIO)-enhanced MRI Imaging influence on surgery Noninvasive detection of pelvic lymph node metastases Influence of imaging protocol on surgical outcome |
Urinary Tract Neoplasm Cystocele Genital Neoplasms, Male Prostatic Diseases Urinary Bladder Diseases Urinary Bladder Neoplasms Urogenital Neoplasms |
Urologic Neoplasms Genital Diseases, Male Urologic Diseases Neoplasm Metastasis Bladder Neoplasm Prostatic Neoplasms |
Prostatic Diseases Genital Neoplasms, Male Urinary Bladder Diseases Urinary Bladder Neoplasms Urogenital Neoplasms Urologic Neoplasms Genital Diseases, Male |
Neoplasms Neoplastic Processes Neoplasms by Site Pathologic Processes Urologic Diseases Neoplasm Metastasis Prostatic Neoplasms |